2005
Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials
Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA. Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials. Journal Of Clinical Oncology 2005, 23: 8081-8092. PMID: 16204011, DOI: 10.1200/jco.2005.02.7078.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsBiomarkers, TumorCarcinoma, Non-Small-Cell LungErbB ReceptorsFemaleGefitinibGene AmplificationGene Expression Regulation, NeoplasticHumansLung NeoplasmsMaleMiddle AgedMutationQuinazolinesReverse Transcriptase Polymerase Chain ReactionSequence Analysis, DNASurvival RateConceptsEpidermal growth factor receptorCell lung cancerEGFR mutationsLung cancerEpidermal growth factor receptor (EGFR) mutationsTrials of gefitinibLarge clinical trialsCombination of gefitinibLung cancer specimensGene amplificationEGFR gene amplificationAdenocarcinoma histologyBiologic subsetsGrowth factor receptorIDEAL trialINTACT trialsSmoking historyClinical featuresEGFR genotypeFemale sexClinical trialsGefitinib responseGefitinib trialsCancer specimensAsian ethnicity
2003
Gefitinib: current and future status in cancer therapy.
Herbst RS, Kies MS. Gefitinib: current and future status in cancer therapy. Clinical Advances In Hematology And Oncology 2003, 1: 466-72. PMID: 16258434.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorTumor growthEGFR tyrosine kinase inhibitorsCurrent clinical development statusOngoing clinical trialsCombination of gefitinibClinical development statusCancer cell growthHost-dependent processesGrowth factor receptorHormonal therapyStandard chemotherapyBiologic agentsDisease recurrenceCell lungSolid malignanciesClinical trialsTumor cell functionsViable drug targetNovel agentsPreclinical studiesClinical developmentTumor typesGefitinibKinase inhibitors